


November 7, 2025

Wood-Derived Material “Sulfated Hemicellulose” Obtains Approval as Veterinary Pharmaceutical API in Australia

Oji Holdings Corporation (CEO: Hiroyuki Isono, Head Office: Chuo-ku, Tokyo) hereby announces that its group company, Oji Pharma Co., Ltd. (President: Kotaro Ishikawa, Head Office: Chuo-ku, Tokyo), has obtained approval in Australia—effective September 30, 2025—for the manufacture and export of sulfated hemicellulose (chemical name: Pentosan Polysulfate Sodium (PPS)) as an active pharmaceutical ingredient (API) for veterinary use.

Since its establishment in April 2020, Oji Pharma has been strengthening its research, development and manufacturing capabilities for veterinary and human pharmaceuticals derived from wood-based and biomass materials, and advancing the establishment of domestic and international pharmaceutical manufacturing and marketing systems.

Building on Oji Group’s long-standing practice of natural capital management rooted in the sustainable stewardship of forest resources, we are expanding into veterinary medicine, rare animal care, pharmaceuticals and medical devices to realize a “Nature-Positive Medical Model” that balances ecosystem conservation with improved access to medical care. Securing API approval in Australia represents a key milestone in the global rollout of this model.



With this approval, Oji Pharma will further solidify its API supply system in compliance with international GMP (Good Manufacturing Practice) and regulatory standards, accelerating the establishment and expansion of a global supply chain. In addition to serving the Australian market, we will target major markets in North America, Europe and Asia, building a sustainable, reliable pharmaceutical supply network and maintaining consistent quality control based on Oji Group’s forest-derived traceability and integrated supply-chain management.

Oji Group remains committed to leveraging its abundant forest resources and proprietary development technologies to contribute to society across the medical and healthcare fields.

Contact

Business Planning Department,
Oji Pharma Co., Ltd.

Phone: +81-3-3520-9888 E-mail: ojipharma-info@oji-gr.com

Public Relations and Investor Relations Department, Corporate Governance Division,
Oji Holdings Corporation <https://www.ojiholdings.co.jp/en/>

Phone: +81-3-3563-4523 E-mail: oji-holdings@oji-gr.com